AlphAIAlphAI — Financial news for AI agents
investing.comSEP 232 min read$PM

UBS raises Philip Morris stock price target to $193 on ZYN pricing

UBS raised its price target on Philip Morris (PM) to $193, maintaining a Neutral rating. The stock trades at $189, above its Fair Value. UBS lowered its 2027 ZYN sales growth forecast to 3% from 19% due to pricing changes. PM plans to reduce ZYN pouch count per can by 25%. UBS cut its 2027 group organic sales growth estimate to 6.4% from 6.9%. PM's dividend yield is 3.4%, with 18 consecutive years of increases. Stifel reiterated a Buy rating with a $205 target, citing smoke-free product growth.

Original reporting
investing.com
Published Sep 23, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PM
Neutral
medium confidence
Mentioned
$PM
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PMNeutralMed
01

Why it matters

Analyst target cut and sales forecast reduction provide fresh data for traders evaluating the stock.

02

Market read

The revision may prompt short‑term price adjustments and influence sector sentiment.

03

What to watch

The $75 million Altria contract and double‑down on Colorado manufacturing investment may offset growth concerns.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

UBS analyst report updates valuation and growth assumptions for Philip Morris International.

Company-level read

Ticker impact

$PMNeutralMedium confidence
Context

UBS raised its price target on Philip Morris International to $193 and lowered its FY2027 ZYN sales growth forecast.

Expected impact

Potential modest downside as investors reassess valuation.

Evidence & confidence

Target below market suggests overvaluation; reduced ZYN growth adds downside risk.

Market effects

Sector

Lower ZYN growth outlook may affect the broader nicotine‑pouch sector.

Regional

US tobacco stocks could see slight pressure.

Global

Minimal, limited to tobacco and smoke‑free product investors.

Counterpoint

What could challenge this read

Despite the lower target, the stock's strong margins and dividend yield could support price stability.

Key entities

  • company
    Philip Morris International

    Tobacco company with smoke‑free product portfolio.

  • analyst
    UBS

    Equity research firm issuing the price target revision.

Read at source← All news

Related articles

SEP 23
$MOMed

Trump administration plans to speed approvals of vapes and nicotine pouches - WSJ

The Trump administration plans to speed up approvals for smoke-free nicotine products like vapes and nicotine pouches, easing FDA review requirements. This benefits tobacco companies such as Altria (MO), Philip Morris (PM), and British American Tobacco (BTI), which face regulatory delays. The move aims to reduce illegal products but faces opposition from health advocates concerned about youth access.

investing.com2 min
SEP 10
$PMHighAI 8/10

Why is Philip Morris International stock climbing today?

Philip Morris International (PM) stock rose 2.1% after updating its Q3 2026 EPS guidance to $2.29-$2.34, exceeding estimates. The company also raised its full-year 2026 EPS forecast to $8.35-$8.50, citing favorable currency impacts. Analysts increased price targets to $205-$225. PM's defensive profile and smoke-free products supported the stock amid broader market declines.

investing.com2 min
SEP 9
$PMMedAI 8/10

FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?

Philip Morris (NYSE:PM) received FDA authorization for 11 nicotine-pouch products, including higher-strength Zyn Ultra pouches. The company aims to expand its market share in the fastest-growing US nicotine category, but lower pricing and increased investment may impact profitability. The FDA cited lower harmful constituents compared to other tobacco products. PM plans to invest more in Zyn as competition intensifies, particularly against British American Tobacco's Velo brand. However, the succe

yahoo.com2 min
SEP 8
$PMMedAI 8/10

PM Looks 16.9% Overvalued on GF Value™ as Dividend Sustainabilit

Philip Morris International (NYSE: PM) raised its full-year adjusted diluted EPS forecast to $7.28-$7.43, reflecting 10.7%-12.7% growth. CEO Jacek Olczak highlighted strong pricing power and profit growth at the Barclays Global Consumer Conference. The stock, trading at $185.07, is 16.9% overvalued relative to its GF Value™ of $158.36, with a 3.16% dividend yield and a 73% payout ratio.

gurufocus.com2 min
SEP 8
$PMHighAI 8/10

Philip Morris International Inc. (PM): Regulation FD Disclosure

Philip Morris International Inc. (PM) filed an SEC Form 8-K — Regulation FD Disclosure. Championing a Smoke-Free World Barclays Global Consumer Conference September 8, 2026 Jacek Olczak Group CEO PMI Introduction • A glossary of terms as well as adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures for non-GAAP financ

SEC EDGAR 8-K2 min